tetano
Editor, Senior Moderator
Open Forum Infect Dis. 2017 May 18;4(3)
fx105. doi: 10.1093/ofid/ofx105. eCollection 2017 Summer.
[h=1]A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.[/h] Abed Y[SUP]1[/SUP], Boivin G[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics and eventual pandemics. Thus, the emergence of NAI resistance could be a major clinical concern. Although most currently circulating influenza A and B strains are susceptible to NAIs, clinical cases of influenza viruses harboring single or multiple NA substitutions or deletions conferring a cross-resistance phenotype to the 2 main NAIs (oseltamivir and zanamivir) have been reported, mostly in immunocompromised individuals. Moreover, such events seem to be more frequent in A(H1N1)pdm09 viruses containing the H274Y substitution together with other NA changes (I222R, E119D/G). This review summarizes the therapeutic regimens leading to the emergence of NAI cross-resistant influenza A and B viruses as well as the virologic properties of such variants.
[h=4]KEYWORDS:[/h] influenza; neuraminidase; oseltamivir; resistance; zanamivir
PMID: 28852674 PMCID: PMC5569976 DOI: 10.1093/ofid/ofx105
fx105. doi: 10.1093/ofid/ofx105. eCollection 2017 Summer.[h=1]A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.[/h] Abed Y[SUP]1[/SUP], Boivin G[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics and eventual pandemics. Thus, the emergence of NAI resistance could be a major clinical concern. Although most currently circulating influenza A and B strains are susceptible to NAIs, clinical cases of influenza viruses harboring single or multiple NA substitutions or deletions conferring a cross-resistance phenotype to the 2 main NAIs (oseltamivir and zanamivir) have been reported, mostly in immunocompromised individuals. Moreover, such events seem to be more frequent in A(H1N1)pdm09 viruses containing the H274Y substitution together with other NA changes (I222R, E119D/G). This review summarizes the therapeutic regimens leading to the emergence of NAI cross-resistant influenza A and B viruses as well as the virologic properties of such variants.
[h=4]KEYWORDS:[/h] influenza; neuraminidase; oseltamivir; resistance; zanamivir
PMID: 28852674 PMCID: PMC5569976 DOI: 10.1093/ofid/ofx105